Investing
Metabasis Therapeutics (MBRX): Another Biopharma Microcap Implodes
Published:
Metabasis Therapeutics (MBRX) is off 56% to $3 after its diabetes drug candidate CS-917 failed to significantly lower blood sugar in a mid-stage trial. The company has traded as high as $8.64 in the last year.
It is another example of the "one trick pony" microcap biopharma’s that have nothing to offer but a one product trial. In the last quarter, the company lost over $9 million on revenue of $3.4 million. It loss has been about the level for each of the last four quarters. Add to this that the company had a market cap of $250 million within the last year.
Amazing risk.
Douglas A. McIntyre
Take This Retirement Quiz To Get Matched With A Financial Advisor (Sponsored)
Take the quiz below to get matched with a financial advisor today.
Each advisor has been vetted by SmartAsset and is held to a fiduciary standard to act in your best interests.
Here’s how it works:
1. Answer SmartAsset advisor match quiz
2. Review your pre-screened matches at your leisure. Check out the advisors’ profiles.
3. Speak with advisors at no cost to you. Have an introductory call on the phone or introduction in person and choose whom to work with in the future
Take the retirement quiz right here.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Editors' Picks
